MedTrace Logo

Cholecalciferol Supplementation for Anemia and Mineral and Bone Disorder in Hemodialysis Patients

NCT02214563 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2018-08-31

No results posted yet for this study

Summary

The purpose of this study is to determine whether cholecalciferol supplementation decrease the blood concentrations of hepcidin-25 in hemodialysis patients.

Conditions

  • Kidney Failure, Chronic
  • Anemia
  • Vitamin D Deficiency
  • Bone Diseases, Metabolic

Interventions

DIETARY_SUPPLEMENT

Cholecalciferol

Made for this trial by Molecular Physiological Chemistry Laboratory, Inc.

DIETARY_SUPPLEMENT

Olive oil

Sponsors & Collaborators

  • The Japan Kidney Foundation

    collaborator OTHER

  • Molecular Physiological Chemistry Laboratory, Inc.

    collaborator OTHER

  • Obi clinic

    collaborator UNKNOWN

  • Higashikouri Hospital

    collaborator UNKNOWN

  • Nishi clinic

    collaborator UNKNOWN

  • Futaba clinic

    collaborator UNKNOWN

  • Akebono clinic

    collaborator UNKNOWN

  • Takayuki Hamano

    lead OTHER

Principal Investigators

  • Yoshiharu Tsubakihara, MD, PhD · Department of Comprehensive Kidney Disease Research, Osaka University Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2016-03-31
Completion
2016-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02214563 on ClinicalTrials.gov